When Geneticists and Clinicians Mate, Outcomes Database
Executive Summary
Sequana's agreement with Memorial Sloan-Kettering Cancer Center to form a $10 million joint venture dedicated to cancer genetics is not unlike the genes it seeks to uncover-it is unique in both structure and function. The still unnamed company, willcorrelate the genotype information gathered from breast, colon, and prostrate cancer tissue samples with Sloan-Kettering's detailed data on the original diagnosis, treatment, and outcomes of these cancers.
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports